Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE432.55-8.5 (-1.93 % )
PREV CLOSE (Rs.) 441.05
OPEN PRICE (Rs.) 440.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 25657
TODAY'S LOW / HIGH (Rs.)426.05 444.05
52 WK LOW / HIGH (Rs.)357.8 661.95
NSE433.15 -8.75 (-1.98 % )
PREV CLOSE(Rs.) 441.90
OPEN PRICE (Rs.) 446.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 433.15 (1949 )
VOLUME 1216110
TODAY'S LOW / HIGH(Rs.) 426.95 446.80
52 WK LOW / HIGH (Rs.)358.1 660

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) 21.25
P/E Ratio 20.35
Book Value (Rs.) 102.49
Face Value (Rs.) 1
MCap (Rs. in Mn) 58731.92
Price/Earning (TTM) 17.77
Price/Sales (TTM) 6.04
Price/Book (MRQ) 4.22
PAT Margin (%) 31.83
ROCE (%) 25.98
Incorporation Year : 2007

Management Info :

- Chairman Amit Indubhushan Bakshi - Managing Director

Registered Office :

Address : 8th Floor, Commerce House I V,Beside Shell Petrol Pump,100 Feet Road, Prahladnagar,
Ahmedabad,
Gujarat-380015

Phone : 079 3045 1111

Website : www.eris.co.in

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
08Feb02-08-2020$Eris Lifesciences submits board meeting intimation Eris Lifesciences submits bo

Eris Lifesciences has submitted the board meeting intimation.

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has submitted the board meeting intimation.Th..
27Jan01-27-2020$Eris Lifesciences informs about updates on buyback offer Eris Lifesciences informs ab

Axis Capital (Manager to Buyback Offer) has submitted a copy of post Buyback Public Announcement for the attention of the Equity Shareholders/ Beneficial Owners of Equity Shares of Eris Lifesciences (Target Company).

The above information is a part of company’s filings submitted to BSE.

Axis Capital (Manager to Buyback Offer) has submitted a copy of..
23Jan01-23-2020$ Corporate Action-Updates on Buy back Corporate Action-Updates on
We wish to inform you that the Company has completed the Buyback of equity shares from the shareholders of the Company, payable in cash via 'tender offer' route, in accordance with the applicable laws including Sections 68, 69 and 70 and other applicable provisions of the Companies Act, 2013, as amended, and the Buy-back Regulations. With respect to the Buy-back, in accordance with the Regulation 24(vi) of the Buy-back Regulations, the public advertisement regarding completion of the Buy-back ('Public Advertisement') was published on January 23, 2020 in Financial Express (English National daily and Regional daily), Jansatta (Hindi national daily). Please find enclosed a copy of the Public Advertisement for your information and record.
We wish to inform you that the Company has completed the Buybac..
26Dec12-26-2019$Eris Lifesciences informs about trading window closure Eris Lifesciences informs ab

Eris Lifesciences has informed that the trading window closure of the Company shall commence from 1st January, 2020 (Wednesday), till 48 hours after the declaration of financial results of the Company for the quarter ending on 31st December, 2019. Further pursuant to ‘Clause 4’ of ‘Schedule B’ of SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company', all the Designated Persons and their immediate relatives are requested not to trade in securities of the Company during the closure of the trading window. This trading window closure notice operates independently and does not intend to amend, alter, modify, curtail, or extend any other notice(s) on the closure of trading window for any other purpose, whether currently in effect or to be issued during the validity of this notice. 

The above information is a part of company’s filings submitted to BSE.

Eris Lifesciences has informed that the trading window closure..
24Dec12-24-2019$Eris Lifesciences submits letter of offer Eris Lifesciences submits le

With reference to Proposed offer for buyback of up to 1,739,130 fully paid up equity shares of face value of Re 1 each at a price of Rs 575 per fully paid up equity share on a proportionate basis through the tender offer process of the Company, Eris Lifesciences has informed about submission of the Letter of Offer, which is dispatched to its equity shareholders as on July 15, 2019, being the record date for Buyback. 

The above information is a part of company’s filings submitted to BSE.

With reference to Proposed offer for buyback of up to 1,739,130..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit626.762853.81
Gross Profit 710.06 3117.76
Operating Profit 826.943661.58
Net Sales 2542.698965.39
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 7322.90 (2.05%)
M.Cap ( in Cr)
16865.09
Ajanta Pharma (BSE)
 1446.05 (10.03%)
M.Cap ( in Cr)
12618.42
Ipca Laboratories (BSE)
 1456.15 (3.43%)
M.Cap ( in Cr)
18398.76
Solara Active Pharma (BSE)
 680.25 (6.01%)
M.Cap ( in Cr)
1772.41
Alkem Laboratories (BSE)
 2657.75 (1.39%)
M.Cap ( in Cr)
31777.39
Shareholding Pattern More
PROMOTERS 56.23 %
NON-INSTITUTION 23.11 %
MUTUAL FUNDS/UTI 11.13 %
FI/BANKS/INSURANCE 0.02 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes